Last reviewed · How we verify
Gatifloxacin 0.5% eye drops
Gatifloxacin 0.5% eye drops is a Fluoroquinolone antibiotic Small molecule drug developed by Allergan. It is currently in Phase 3 development for Bacterial conjunctivitis, Bacterial keratitis, Bacterial corneal ulcer.
Gatifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing bacterial DNA replication and transcription.
Gatifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing bacterial DNA replication and transcription. Used for Bacterial conjunctivitis, Bacterial keratitis, Bacterial corneal ulcer.
At a glance
| Generic name | Gatifloxacin 0.5% eye drops |
|---|---|
| Sponsor | Allergan |
| Drug class | Fluoroquinolone antibiotic |
| Target | Bacterial DNA gyrase and topoisomerase IV |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
As a broad-spectrum fluoroquinolone, gatifloxacin works by binding to and inhibiting bacterial DNA gyrase (in gram-negative bacteria) and topoisomerase IV (in gram-positive bacteria), enzymes essential for DNA replication and repair. This leads to rapid bactericidal activity against a wide range of gram-positive and gram-negative ocular pathogens. The 0.5% ophthalmic formulation delivers high local concentrations to the eye while minimizing systemic absorption.
Approved indications
- Bacterial conjunctivitis
- Bacterial keratitis
- Bacterial corneal ulcer
Common side effects
- Conjunctival irritation
- Eye discomfort or burning
- Taste perversion (from nasolacrimal drainage)
- Photophobia
Key clinical trials
- Prophylactic Treatment: Lessdrops™ vs Standard Drops Regimen (PHASE4)
- Swiss PACK-CXL Multicenter Trial for the Treatment of Infectious Keratitis (PHASE3)
- Safety and Efficacy of PRO-157 vs Moxifloxacin vs Gatifloxacin in Patients With Bacterial Conjunctivitis (Pazufloxacin) (PHASE2)
- A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis (PHASE3)
- A Comparison of Three Fluoroquinolone Topical Eyedrops in the Treatment of Infectious Corneal Ulcers. (PHASE2)
- A Clinical Study to Evaluate if Benzalkonium Chloride (BAK) in a Quinolone Eyedrop Reduces the Likelihood of Developing Resistant Organisms (PHASE4)
- Assessment of the Concentrations of Besifloxacin, Moxifloxacin, or Gatifloxacin in the Aqueous Humor of Subjects (PHASE1)
- Concentration of Besifloxacin, Gatifloxacin, and Moxifloxacin in Human Conjunctiva After Topical Instillation (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Gatifloxacin 0.5% eye drops CI brief — competitive landscape report
- Gatifloxacin 0.5% eye drops updates RSS · CI watch RSS
- Allergan portfolio CI
Frequently asked questions about Gatifloxacin 0.5% eye drops
What is Gatifloxacin 0.5% eye drops?
How does Gatifloxacin 0.5% eye drops work?
What is Gatifloxacin 0.5% eye drops used for?
Who makes Gatifloxacin 0.5% eye drops?
What drug class is Gatifloxacin 0.5% eye drops in?
What development phase is Gatifloxacin 0.5% eye drops in?
What are the side effects of Gatifloxacin 0.5% eye drops?
What does Gatifloxacin 0.5% eye drops target?
Related
- Drug class: All Fluoroquinolone antibiotic drugs
- Target: All drugs targeting Bacterial DNA gyrase and topoisomerase IV
- Manufacturer: Allergan — full pipeline
- Therapeutic area: All drugs in Ophthalmology / Infectious Disease
- Indication: Drugs for Bacterial conjunctivitis
- Indication: Drugs for Bacterial keratitis
- Indication: Drugs for Bacterial corneal ulcer